Preclinical Proof of Concept for a personalized SNAPTM-TIL (Specific Neo-Antigen Peptides -TIL) therapy platform
Tithi Ghosh, Erin Kelley, Jorge Soria‐Bustos, Trason G. Thode, Serina Ng, Taylor Bargenquast, Alexis Weston, Ryan Rodriguez del Villar, Mohan Rao Kaadige, Erkut Hasan Borazanci, Michael S. Gordon, Justin Moser, Frank Yung-Chin Tsai, Saul J. Priceman, Stephen J. Forman, , Sunil Sharma
This paper demonstrates a personalized SNAP-TIL therapy platform that improves TIL efficacy by enriching them with neoantigen-reactive T-cells, achieving high CD3+ cell content and significant tumor growth inhibition in preclinical models.
OncoImmunology · Jul 5, 2026Peer-reviewedImmunology